AstraZeneca plc (LON:AZN) and MSD’s
Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.
The three approvals authorise
Lynparza for: maintenance treatment after 1st-line chemotherapy containing bevacizumab (genetical recombination) for patients with homologous recombination repair deficient (HRD) ovarian cancer; the treatment of patients with BRCA gene-mutated (BRCAm) castrate-resistant prostate cancer with distant metastasis (mCRPC); and as maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare are based on positive results from the PAOLA-1, PROfound and POLO Phase III trials, which each were published in
29 December 2020 | 07:10am
StockMarketWire.com - Pharmaceutical giants AstraZeneca and MSD said their drug to treat advanced ovarian, prostate, and pancreatic cancers had been approved in Japan.
The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare were based on positive results from the PAOLA-1, PROfound and POLO phase three trials, which each were published in The New England Journal of Medicine, the companies said.
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Latest share price and company details:
AstraZeneca s Lynparza Gets Approval In Japan To Treat Three Cancers
Mon, 28th Dec 2020 08:05
(Alliance News) - AstraZeneca PLC said Monday its Lynparza cancer treatment has secured approval in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.
Astra jointly develops and commercialises the drug with US pharmaceutical company Merck & Co Inc. The pair signed a global strategic oncology collaboration to co-develop and co-commercialise Lynparza in July 2017.
The concurrent approvals by the Japanese Ministry of Health, Labour & Welfare are based on positive results from the PAOLA-1, PROfound and POLO Phase III trials, which, Astra noted, were published in The New England Journal of Medicine.
LYNPARZA® (olaparib) Receives Three New Approvals in Japan businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca: Japan Approves Lynparza To Treat Three Types Of Advanced Cancer
LONDON (dpa-AFX) - AstraZeneca Plc. (AZN.L, AZN) and Merck & Co Inc. (MRK) said that Japan has approved Lynparza or olaparib for the treatment of three types of advanced cancer: ovarian, prostate and pancreatic cancer.
The companies stated that the approvals authorize Lynparza for use as maintenance treatment after first-line chemotherapy containing bevacizumab in patients with homologous recombination repair deficient (HRD) ovarian cancer; the treatment of patients with BRCA gene-mutated or BRCAm castration-resistant prostate cancer with distant metastasis or mCRPC; and maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.